LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 384

Search options

  1. Book ; Online ; E-Book: Drugs and the FDA

    Sekeres, Mikkael A.

    safety, efficacy, and the public's trust

    2022  

    Author's details Mikkael A. Sekeres
    Language English
    Size 1 Online-Ressource (256 Seiten), Illustrationen, Diagramme
    Publisher MIT Press
    Publishing place Cambridge, Massachusetts
    Publishing country United States
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT021492193
    ISBN 9780262371315 ; 9780262047319 ; 0262371316 ; 0262047314
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Article ; Online: Combining lenalidomide with erythropoiesis stimulating agents: a party of one.

    Chandhok, Namrata S / Sekeres, Mikkael A

    Leukemia

    2024  Volume 38, Issue 3, Page(s) 473–474

    MeSH term(s) Humans ; Lenalidomide/pharmacology ; Hematinics/therapeutic use ; Hematinics/pharmacology ; Thalidomide/therapeutic use ; Thalidomide/pharmacology ; Myelodysplastic Syndromes ; Erythropoiesis
    Chemical Substances Lenalidomide (F0P408N6V4) ; Hematinics ; Thalidomide (4Z8R6ORS6L)
    Language English
    Publishing date 2024-02-15
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-024-02176-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Transplant.

    Sekeres, Mikkael A

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2021  Volume 39, Issue 28, Page(s) 3185–3187

    MeSH term(s) Attitude of Health Personnel ; Career Choice ; Career Mobility ; Humans ; Interpersonal Relations ; Licensure, Medical ; Oncologists ; Workplace
    Language English
    Publishing date 2021-06-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.21.01070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Raising the bar for lower-risk myelodysplastic syndromes.

    Venugopal, Sangeetha / Sekeres, Mikkael A

    Leukemia & lymphoma

    2023  Volume 64, Issue 6, Page(s) 1082–1091

    Abstract: Myelodysplastic syndromes (MDS) are broadly categorized as lower- and higher-risk with lower-risk dominated by cytopenias and higher-risk plagued by the risk of transformation to acute myeloid leukemia (AML). The management of MDS utilize a risk-adapted ... ...

    Abstract Myelodysplastic syndromes (MDS) are broadly categorized as lower- and higher-risk with lower-risk dominated by cytopenias and higher-risk plagued by the risk of transformation to acute myeloid leukemia (AML). The management of MDS utilize a risk-adapted approach aimed at ameliorating cytopenias in lower-risk MDS (LR-MDS) and preventing AML transformation in higher-risk MDS. Hematopoietic stem cell transplantation is a potentially curative intent therapy in higher-risk MDS; however, it is not routinely recommended in LR-MDS in view of unfavorable risk/benefit ratio. Therefore, the goal of treatment in LR-MDS is aimed at improving the transfusion burden and health related quality of life. Currently, erythropoiesis stimulating agents (recombinant erythropoietin), erythroid maturation agents (luspatercept), disease modifying agents (lenalidomide) and hypomethylating agents are the agents of choice in the treatment of LR-MDS. This review will discuss the current treatment standards, meaningful clinical outcomes, and emerging therapies in LR-MDS.
    MeSH term(s) Humans ; Prognosis ; Quality of Life ; Myelodysplastic Syndromes/therapy ; Myelodysplastic Syndromes/drug therapy ; Anemia ; Risk Assessment ; Leukemia, Myeloid, Acute
    Language English
    Publishing date 2023-04-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2023.2197536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Trying to Remember How We Saw Patients on That April Morning.

    Sekeres, Mikkael A

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2020  Volume 39, Issue 2, Page(s) 170–171

    MeSH term(s) Attitude of Health Personnel ; Humans ; Medical Oncology ; Middle Aged ; Myelodysplastic Syndromes/therapy ; Physicians ; Telemedicine
    Language English
    Publishing date 2020-06-09
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.20.01184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Parsing the Paradox of Myelodysplastic Syndromes.

    Sekeres, Mikkael A

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2020  Volume 39, Issue 1, Page(s) 4–6

    MeSH term(s) Humans ; Myelodysplastic Syndromes ; Oligonucleotides
    Chemical Substances Oligonucleotides ; imetelstat (F60NE4XB53)
    Language English
    Publishing date 2020-12-04
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.20.02964
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Under COVID of the night.

    Sekeres, Mikkael A

    Blood

    2020  Volume 136, Issue 25, Page(s) 2844–2845

    MeSH term(s) COVID-19 ; Circadian Rhythm ; Hematologic Neoplasms ; Humans ; SARS-CoV-2
    Language English
    Publishing date 2020-12-14
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2020009377
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book: Clinical malignant hematology

    Sekeres, Mikkael A.

    2007  

    Title variant Hematology
    Author's details ed. Mikkael A. Sekeres
    Keywords Hematologic Neoplasms ; Hematologic Neoplasms / therapy ; Hematopoietic Stem Cell Transplantation
    Language English
    Size XXII, 1201 S., [8] Bl. : Ill.
    Publisher McGraw-Hill
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT014497217
    ISBN 978-0-07-143650-2 ; 0-07-143650-2
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  9. Article ; Online: An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.

    Pleyer, Lisa / Sekeres, Mikkael A

    The Lancet. Haematology

    2022  Volume 9, Issue 10, Page(s) e714–e716

    MeSH term(s) Azacitidine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Humans ; Leukemia, Myeloid, Acute ; Myelodysplastic Syndromes/drug therapy ; Sulfonamides/therapeutic use
    Chemical Substances Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides ; Azacitidine (M801H13NRU) ; venetoclax (N54AIC43PW)
    Language English
    Publishing date 2022-09-02
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2352-3026
    ISSN (online) 2352-3026
    DOI 10.1016/S2352-3026(22)00252-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: What constitutes meaningful improvement in myelodysplastic syndromes?

    Chandhok, Namrata S / Sekeres, Mikkael A

    Leukemia & lymphoma

    2022  Volume 63, Issue 11, Page(s) 2528–2535

    Abstract: Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild ... ...

    Abstract Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild asymptomatic anemia to a markedly truncated life expectancy, underscoring the importance of risk-adapted therapy. MDS therapy for both lower- and higher-risk patients is an area of immense therapeutic opportunity. This is partly due to the diversity of treatment goals between patients and defining what constitutes meaningful benefit from a patient's viewpoint. Correlating metrics such as hematologic improvement or response rate to develop novel therapies can be falsely reassuring to physicians and patients, specifically if the interventions are burdensome, disconnected from a patient's sense of wellbeing and do not correlate with an improvement in quality of life or longevity. We discuss aligning drug development goals with patient goals that will lead to meaningful improvement in MDS clinical care.
    MeSH term(s) Humans ; Quality of Life ; Myelodysplastic Syndromes/therapy ; Myelodysplastic Syndromes/drug therapy ; Leukemia, Myeloid, Acute ; Hematopoiesis ; Thrombocytopenia ; Anemia
    Language English
    Publishing date 2022-06-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2022.2084732
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top